Evidence map›Paper›PMID 41234446›Full record

ArticleTurkish journal of medical sciences2025

Do the expressions of HLA-G and killer cell immunoglobulin-like receptors change in colorectal cancer?

Ezgi Dinçer, Fatma Kaya Dağistanli, Kıvanç Derya Peker, Damlanur Sakiz, Figen Abatay Sel, Demet Kivanç, Hayriye Şentürk Çiftçi, Çiğdem Kekik Çinar, Şule Karataş, Fatma Savran Oğuz

Abstract read
In one paragraph

Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ezgi DinçerInstitute of Graduate Studies in Health Science, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0009-0001-8980-0375
Fatma Kaya DağistanliDepartment of Medical Biology, Cerrahpasa Faculty of Medicine, İstanbul University-Cerrahpasa, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-4672-8721
Kıvanç Derya PekerDivison of Gastroenterology, Department of Surgery, Hisar Hospital Intercontinental, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-8887-3505
Damlanur SakizDepartment of Pathology, University of Health Sciences Bakırkoy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-2051-1049
Figen Abatay SelInstitute of Graduate Studies in Health Science, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-1155-1284
Demet KivançDepartment of Medical Biology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-2451-5709
Hayriye Şentürk ÇiftçiDepartment of Medical Biology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0001-5160-5227
Çiğdem Kekik ÇinarDepartment of Medical Biology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0003-2098-381X
Şule KarataşInstitute of Graduate Studies in Health Science, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-8605-4178
Fatma Savran OğuzDepartment of Medical Biology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-6018-8936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: The immune system functions as a well-coordinated defense mechanism, protecting the host from both external pathogens and internal threats. Cancer cells often display surface antigens that the immune system can recognize as foreign, potentially triggering an immune response. However, many cancer cells evade detection by downregulating or completely losing these surface antigens. The immune system relies on the expression of surface antigens and human leukocyte antigens (HLA) to identify and target tumor cells. One key method by which tumor cells evade natural killer (NK) cells involves alterations in HLA antigens.Colorectal cancer (CRC) is known to cause various changes in the immune system, including the increased expression of HLA antigens on cell surfaces, reduced functionality of NK cells, and mechanisms for immune evasion.The aim of this study was to investigate the possible roles of innate immunity and associated HLA-G molecules in the development of CRC by examining tumor tissue samples. Materials and methods: We evaluated soluble HLA-G (sHLA-G) levels via ELISA, investigated HLA-G expression loss in tumor samples through immunohistochemistry (IHC), and assessed killer cell immunoglobulin-like receptor (KIR) expression on NK cells in tumor tissues. Results: No significant correlation was found between HLA-G and sHLA-G levels (p = 0.641). Among patient samples, 16.7% (6 of 36) were positive for HLA-G, with varying intensities, while no staining was observed in control samples. Compared to control samples, IHC staining revealed a significantly higher rate of KIR positivity in CRC tissue samples. One notable finding of our study was the variability in KIR staining intensity within the same tumor. We observed differences in KIR expression not only between tumors, but also within distinct areas of the same tumor. Additionally, a significant relationship was found between KIR expression and age. Conclusion: In conclusion, this study highlights the increased expression of both HLA-G and KIR markers in CRC patients, suggesting their potential as prognostic and predictive markers. Our findings also suggest that HLA-G and KIR molecules could represent valuable therapeutic targets for future cancer immunotherapy strategies.

Indexed as

Colorectal NeoplasmsHLA-G AntigensKiller Cells, NaturalReceptors, KIRAdultAgedCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHealthy VolunteersHumansImmunity, InnateImmunohistochemistryMaleMiddle AgedTumor EscapeHLA-G AntigensReceptors, KIRcolorectal cancerHuman leukocyte antigen-Gkiller cell immunoglobulin-like receptor

Identifiers

PMID41234446
PMCPMC12611366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.